View Clinical Trial (Medical Research Study)
Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas
| City: |
|
Seattle |
| State: |
|
Washington |
| Zip Code: |
|
98109 |
| Conditions: |
|
Adult Giant Cell Glioblastoma - Adult Glioblastoma - Adult Gliosarcoma |
| Purpose: |
|
This phase I/II trial is studying carmustine and temozolomide when given together with
radiation therapy, BCNU, O6-benzylguanine, and an autologous stem cell transplant in
treating patients with newly diagnosed glioblastoma multiforme or gliosarcoma. Giving
chemotherapy, such as temozolomide, carmustine, and O6-benzylguanine, and radiation therapy
before a peripheral stem cell transplant stops the growth of cancer cells by stopping them
from dividing or killing them. Giving colony-stimulating factors, such as filgrastim, and
certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they
can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the
bone marrow for the stem cell transplant. The stem cells are then returned to the patient to
replace the blood-forming cells that were destroyed by the chemotherapy and radiation
therapy
|
| Study Summary: |
|
PRIMARY OBJECTIVES:
I. Determine the safety and feasibility of infusing autologous G-CSF (filgrastim) and
plerixafor (Mozobil) mobilized stem cells transduced with a Phoenix-GALV-pseudotype vector
expressing methylguanine methyltransferase (MGMT) (P140K).
II. Define the dose of BCNU (carmustine) that results in efficient engraftment of gene
modified cells when given with peripheral blood stem cell support.
SECONDARY OBJECTIVES:
I. Determine the engraftment of gene-modified cells after conditioning with BCNU.
II. Determine the ability to select gene-modified cells in vivo with this regimen.
III. Evaluate the molecular and clonal composition of gene-modified cells after chemotherapy
with temozolomide. IV. Observe patients for clinical anti-tumor response. V. Determine the
correlation of the level of MGMT (P140K) marking with toxicity, temozolomide dose achieved,
and response.
VI. Characterize the toxicity associated with this regimen.
OUTLINE: This is a phase I, dose-escalation study of temozolomide followed by a phase II
study.
PHASE I: Patients undergo radiotherapy 5 days per week for 7 weeks. Patients receive
filgrastim subcutaneously (SC) on days -7 to -3 and begin stem cell collection on the 4th
day of filgrastim administration (up to 3 aphereses). Plerixafor will be used if the CD34+
cell collection from the first apheresis is low or if on day 3 of mobilization the
peripheral stem cell count is <5/mcL with G-CSF alone. The CD34+ stem cells are separated
from the patient's stem cells and they are transduced with Phoenix-RD114 pseudotype vector
(retrovirus). One day after apheresis is completed, patients receive carmustine
intravenously (IV) over 1 hour followed 2 hours later by temozolomide orally (PO). At least
twenty-four hours after completion of carmustine and temozolomide, patients undergo
reinfusion of genetically-modified stem cells.
PHASE II: Beginning approximately 4 weeks after completion of phase 1 of the study, patients
receive O6-benzylguanine IV continuously over 48 hours followed 2 hours later by
temozolomide PO. Treatment may repeat at least every 28 days for a total of 24 courses in
the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed every 1-3 months for the first 2
years, every 3-6 months for 3 years, and annually thereafter for up to 15 years.
|
| Criteria: |
|
Inclusion Criteria:
- Patients with glioblastoma multiforme or gliosarcoma
- The patient or legal guardian must be able to comprehend the informed consent form
and sign prior to patient enrollment
- Patients must be consented for MGMT promoter methylation analysis of brain tumor
tissue within twenty-eight days after surgery
- Karnofsky performance status at time of study entry must be >= 70%
- Life expectancy of >= 3 months
- Patients must agree to undergo repeat clinical neurological examinations and brain
magnetic resonance imaging (MRI) with appropriate contrast after every other cycle of
chemotherapy
- White blood cell (WBC) > 3000/uL
- Absolute neutrophil count (ANC) > 1500/uL
- Platelets > 100,000/uL
- Hemoglobin > 10 gm/100mL
- Total and direct bilirubin < 1.5 times upper limit of laboratory normal
- Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase
(SGPT), and alkaline phosphatase =< 3 times upper limit of laboratory normal
- Blood urea nitrogen (BUN) and serum creatinine < 1.5 times upper limit of laboratory
normal
- Left ventricular ejection fraction (LVEF) >= 40%, however, subjects with an LVEF in
the range of 40-49% should have cardiology clearance prior to intervention
- MGMT promoter methylation analysis of surgically resected tumor or tumor biopsy must
demonstrate an unmethylated or hypomethylated MGMT promoter status
Exclusion Criteria:
- Patients with cardiac insufficiency and an LVEF of < 40%; history of coronary artery
disease or arrhythmia, which has required or requires ongoing treatment
- Patients with active pulmonary infection and/or pulse oximetry < 90% and a corrected
diffusion capacity of carbon monoxide (DLCO) < 70% of predicted
- Active systemic infection
- Patients who are human immunodeficiency virus (HIV) positive
- Pregnant or lactating women; a beta-human chorionic gonadotropin (HCG) level will be
obtained from women of childbearing potential; fertile men and women should use
effective contraception
- Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC)
or prior nitrosourea
- Diabetes mellitus
- Bleeding disorder
- Methylated or hypermethylated MGMT promoter status within tumor tissue
- Medical or psychiatric condition which in the opinion of the protocol chairman would
compromise the patient's ability to tolerate this protocol
- Prior interstitial radiotherapy, stereotactic or gamma knife surgery or implanted
BCNU-wafers
|
| NCT ID: |
|
NCT00669669 |
| Primary Contact: |
|
Principal Investigator
Hans-Peter Kiem
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Seattle, Washington 98109
United States
Hans-Peter P. Kiem
Phone: 206-667-4425
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|